Dr. Abascal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
One Levy Pl
Box 1030
New York, NY 10029Phone+1 212-241-4022Fax+1 212-426-6376
Education & Training
Boston University Medical CenterFellowship, Cardiovascular Disease, 1992 - 1995
UMass Chan Medical SchoolResidency, Internal Medicine, 1989 - 1992
Central University of VenezuelaClass of 1983
Certifications & Licensure
NY State Medical License 2003 - 2025
KY State Medical License 1998 - 2004
MA State Medical License 1991 - 2002- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- 6 citationsRationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.Maeve Soto Pérez, Jorge Rodríguez-Capitán, Juan Antonio Requena-Ibáñez, Carlos G Santos-Gallego, M Urooj Zafar
Cardiovascular Drugs and Therapy. 2023-06-15 - 278 citationsRandomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.Carlos G. Santos-Gallego, Ariana P. Vargas-Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, Donna M. Mancini
Journal of the American College of Cardiology. 2021-01-26 - 49 citationsRationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?Carlos G. Santos-Gallego, Alvaro Garcia-Ropero, Donna M. Mancini, Sean Pinney, Johanna Contreras
Cardiovascular Drugs and Therapy. 2019-01-24
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
